👍_老虎社区_美港股上老虎

Gabrielle_20
2022-01-18

👍

Moderna CEO says data for Omicron-specific shot likely available in March

Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm

Moderna CEO says data for Omicron-specific shot likely available in March

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":697616018,"tweetId":"697616018","gmtCreate":1642437202639,"gmtModify":1642437203171,"author":{"id":3569531614182731,"idStr":"3569531614182731","authorId":3569531614182731,"authorIdStr":"3569531614182731","name":"Gabrielle_20","avatar":"https://static.tigerbbs.com/3687c03e4fcd937f9b3fa40fa7705b14","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":9,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>👍</p></body></html>","htmlText":"<html><head></head><body><p>👍</p></body></html>","text":"👍","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/697616018","repostId":2204577605,"repostType":4,"repost":{"id":"2204577605","kind":"highlight","pubTimestamp":1642431461,"share":"https://www.laohu8.com/m/news/2204577605?lang=&edition=full","pubTime":"2022-01-17 22:57","market":"us","language":"en","title":"Moderna CEO says data for Omicron-specific shot likely available in March","url":"https://stock-news.laohu8.com/highlight/detail?id=2204577605","media":"Reuters","summary":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical developm","content":"<html><head></head><body><p>Moderna Inc&#39;s vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.</p><p>&#34;The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,&#34; Bancel said at the World Economic Forum&#39;s virtual Davos Agenda conference.</p><p>Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()</p><p>Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.</p><p>&#34;Our goal is to be able to have a single annual booster so that we don&#39;t have compliance issues where people don&#39;t want to get two to three shots a winter.&#34;</p><p>Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.</p><p>Earlier in January, Moderna&#39;s CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.</p><p>However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union&#39;s drug regulator, which has expressed doubts about the need for a fourth booster dose.</p><p>Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.</p><p>&#34;Giving boosters at different times, there is really no evidence that&#39;s going to hinder (immune response).&#34;</p><p>Fauci said the goal should be to have a booster that induces a response against multiple potential variants.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna CEO says data for Omicron-specific shot likely available in March</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna CEO says data for Omicron-specific shot likely available in March\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 22:57 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around ...</p>\n\n<a href=\"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4532":"文艺复兴科技持仓","BK4568":"美国抗疫概念","BK4551":"寇图资本持仓","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","BNTX":"BioNTech SE","MRNA":"Moderna, Inc.","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)"},"source_url":"https://finance.yahoo.com/news/moderna-ceo-says-data-omicron-135958538.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204577605","content_text":"Moderna Inc's vaccine candidate against the Omicron coronavirus variant will enter clinical development in the next few weeks and the company expects to be able to share data with regulators around March, CEO Stephane Bancel said on Monday.\"The vaccine is being finished ... it should be in the clinic in coming weeks. We are hoping in the March timeframe to be able to have data to share with regulators to figure out next steps,\" Bancel said at the World Economic Forum's virtual Davos Agenda conference.Moderna is also developing a single vaccine that combines a booster dose against COVID-19 with its experimental flu shot. ()Bancel said the best case scenario was the combined COVID/flu vaccine would be available by the fall of 2023, at least in some countries.\"Our goal is to be able to have a single annual booster so that we don't have compliance issues where people don't want to get two to three shots a winter.\"Many countries are already offering a third dose of a COVID-19 vaccine to their citizens, especially to older individuals and those who are immunocompromised, while Israel has started offering its citizens a fourth dose.Earlier in January, Moderna's CEO said people may need a fourth shot in the fall of 2022 as the efficacy of boosters against COVID-19 was likely to decline over the next few months.However, booster programs have met with skepticism from some disease experts over whether, and how widely, additional doses should become available, including the European Union's drug regulator, which has expressed doubts about the need for a fourth booster dose.Speaking at the same event, top U.S. infectious disease expert Anthony Fauci said there was no evidence that repeat booster doses would overwhelm the immune system.\"Giving boosters at different times, there is really no evidence that's going to hinder (immune response).\"Fauci said the goal should be to have a booster that induces a response against multiple potential variants.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1105,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":2,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}